Literature DB >> 12547302

Antiepileptic drugs in schizophrenia: a review.

L Hosák1, J Libiger.   

Abstract

The first choice group of psychotropic agents in schizophrenia is neuroleptics. However, this treatment is not effective in all patients and with every symptom. We summarize papers published on the role of antiepileptic drugs in treatment-resistant schizophrenia. We have searched the computer database system MEDLINE for relevant articles including reviews, reports of drug studies and case histories. Antiepileptic drugs can change symptoms of schizophrenia by their action on GABA-ergic neurotransmission or via anti-glutamatergic mechanisms. High doses of adjunctive benzodiazepines reduce positive symptoms, anxiety, and agitation. Carbamazepine is effective in affective symptoms of schizophrenia and influences violent behavior in psychotic patients. Its anti-kindling action may represent a promising treatment strategy for some patients with chronic course of schizophrenia. Valproate treatment leads to a decrease in positive symptoms as well as hostility. Lamotrigine is expected to influence the positive, negative, affective, and cognitive symptoms of schizophrenia. New antiepileptics (e.g., gabapentin, oxcarbazepine, topiramate, vigabatrin) present a promise as potential adjuncts to neuroleptic treatment in resistant symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12547302     DOI: 10.1016/s0924-9338(02)00696-x

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  17 in total

Review 1.  Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships.

Authors:  Renê Oliveira Beleboni; Ruither Oliveira Gomes Carolino; Andrea Baldocchi Pizzo; Lissandra Castellan-Baldan; Joaquim Coutinho-Netto; Wagner Ferreira dos Santos; Norberto Cysne Coimbra
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

2.  Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.

Authors:  Giovan B Cassano; Andrea Fagiolini; Lorenzo Lattanzi; Palmiero Monteleone; Cinzia Niolu; Emilio Sacchetti; Alberto Siracusano; Antonio Vita
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride.

Authors:  Amani Eltayb; Marie-Louise G Wadenberg; Björn Schilström; Torgny H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-12       Impact factor: 3.000

Review 4.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

Review 5.  Potential drug targets and treatment of schizophrenia.

Authors:  Anil Kumar; Monu Yadav; Milind Parle; Sameer Dhingra; Dinesh K Dhull
Journal:  Inflammopharmacology       Date:  2017-03-28       Impact factor: 4.473

6.  Analytical performance evaluation of a new turbidimetric immunoassay for valproic acid on the ADVIA 1650 analyzer: effect of gross hemolysis and high bilirubin.

Authors:  Pradip Datta; Amitava Dasgupta
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

7.  Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study.

Authors:  Adel Gabriel
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-29       Impact factor: 2.570

8.  Concept and Management of Treatment Resistant Schizophrenia (TRS).

Authors:  Nitesh Painuly; Nitin Gupta; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

Review 9.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

Authors:  James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2011-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.